跳到正文
原文
STAT· @statnews · X·· 27 天前AI 评分22
AI 导读

历经四分之一个世纪的努力,德国生物技术公司Immatics正迎来关键时刻,其在研主打候选药物用于黑色素瘤的III期结果即将揭晓。https://trib.al/YoNUC1X

正文

After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma. https://trib.al/YoNUC1X

来源:STAT · x.com